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Why Did the FDA Approve These 
Advertisements?
David Oaks
I would like to thank PLoS Medicine for publishing Lacasse 
and Leo’s important and methodical Essay that debunks 
the “chemical imbalance” advertisements for psychiatric 
drugs [1]. Why would the United States Food and Drug 
Administration (FDA) approve such ads? Our human rights 
group, MindFreedom International, has been asking that 
question for a long time. On behalf of MindFreedom, US 
Senator Ron Wyden contacted the FDA for an explanation 
about why they approve such advertising. In their response—
which took over one year to receive—the FDA could cite 
no scientiﬁ  c literature or studies. It turns out there’s a good 
reason that the FDA can’t ﬁ  nd any scientiﬁ  c evidence for the 
claims of a “chemical imbalance” in these ads: the scientiﬁ  c 
evidence in support of the serotonin hypothesis is very weak.
Readers who would like more information about the 
psychiatric industry’s advertising suggesting a “chemical 
imbalance” in depression may be interested in the following: 
(1) MindFreedom’s debate with Pﬁ  zer, manufacturer 
of Zoloft, available at http:⁄⁄www.mindfreedom.org/
mindfreedom/pﬁ  zerlies.shtml, and (2) a historic debate 
with the American Psychiatric Association resulting from 
MindFreedom’s 2003 hunger strike, available at http:⁄⁄www.
mindfreedom.org/mindfreedom/hungerstrike.shtml 
(Researcher Jonathan Leo was on the MindFreedom 
International Scientiﬁ  c Panel for the hunger strike).  
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Evident Exception in Clinical Practice 
Not Sufﬁ  cient to Break Traditional 
Hypothesis
Milan Sarek
I read with interest the Essay written by Jeffrey R. Lacasse 
and Jonathan Leo [1]. They have found that pharmaceutical 
companies marketing selective serotonin reuptake inhibitors 
(SSRIs) in the United States commonly declare that SSRIs 
correct chemical imbalance in depression caused by a lack 
of serotonin. The authors argue that serotonin deﬁ  ciency 
in depression is scientiﬁ  cally unsupportable; therefore, 
statements about the lack of serotonin should not be used.
I agree with the authors. Nevertheless, I would like to 
add information about another drug that supports their 
arguments. I believe this drug should be mentioned in every 
article describing the serotonin system and depression. The 
drug is not authorized in English-speaking countries (see 
Micromedex Health Series at http:⁄⁄www.micromedex.com), 
and this may possibly explain why the information about its 
controversial mechanism is not largely shared in scientiﬁ  c 
literature.
The name of this drug is tianeptine. It has been used 
for over one decade in several European and some other 
countries (e.g., Brazil, India, Russian Federation, Thailand, 
Turkey, etc.) to relieve depression. Tianeptine increases 
serotonin reuptake; therefore, it has the opposite effect 
on the serotonin system compared with that of SSRIs (see 
Micromedex Health Series at http:⁄⁄www.micromedex.
com) [2,3]. The antidepressant efﬁ  cacy of tianeptine versus 
tricyclics and SSRIs has been demonstrated in several studies 
[2,3]. Because of this opposite action on the serotonin 
system, it has a different adverse event proﬁ  le; e.g., the 
elevated frequency of sexual dysfunction commonly seen after 
SSRIs is not so frequently observed with tianeptine [4]. The 
mechanism of tianeptine’s action is difﬁ  cult to understand, 
but comparing this drug with other antidepressants provides 
us with an intellectual challenge [5].
Tianeptine has been in clinical use for over 12 years in the 
Czech Republic, but statements about serotonin deﬁ  ciency in 
depression are still presented to the public by the media and 
in the patient information leaﬂ  ets accompanying the majority 
of registered SSRIs. One of the reasons for this may be that 
it is difﬁ  cult for the single producer of tianeptine to argue 
against the “traditional” hypothesis that supports the numerous 
leading pharmaceutical companies that market SSRIs. 
For these reasons, I propose that the most direct way 
to conquer the unsupportable, but widely proclaimed, 
concept of serotonin deﬁ  ciency in depression is to act 
through regulatory authorities who are responsible for the 
information given to the public and who also have the power 
to change the information that is provided about registered 
drugs.  
Milan Sarek
Charles University in Prague
Prague, Czech Republic
E-mail: milanosa@centrum.cz
References
1.  Lacasse JR, Leo J (2005) Serotonin and depression: A disconnect between 
the advertisements and the scientiﬁ  c literature. PLoS Med 2: e392. DOI: 
10.1371/journal.pmed.0020392
2.  Wagstaff AJ, Ormrod D, Spencer CM (2001) Tianeptine: A review of its use 
in depressive disorders. CNS Drugs 15: 231–259.
3.  Kasper S, Olie JP (2002) A meta-analysis of randomized controlled trials 
of tianeptine versus SSRI in the short-term treatment of depression. Eur 
Psychiatry 3 (Suppl 17): 331–340. 
4.  Bonierbale M, Lancon C, Tignol J (2003) The ELIXIR study: Evaluation 
of sexual dysfunction in 4557 depressed patients in France. Curr Med Res 
Opin 19: 114–124.
5.  McEwen BS, Olie JP (2005) Neurobiology of mood, anxiety, and emotions 
as revealed by studies of a unique antidepressant: Tianeptine. Mol 
Psychiatry 10: 525–537.PLoS Medicine  |  www.plosmedicine.org 0268
Citation: Sarek M (2006) Evident exception in clinical practice not sufﬁ  cient to 
break traditional hypothesis. PLoS Med 3(2): e120.
Copyright: © 2006 Milan Sarek. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author 
and source are credited.
Competing Interests: The author has declared that no competing interests exist.
DOI: 10.1371/journal.pmed.0030120
Consumer Advertising Can Be 
Misleading
Karl Rickels
The Essay by Lacasse and Leo [1] demonstrates clearly how 
consumer advertising—in all ﬁ  elds of medicine, not only 
psychiatry—can at the least be misleading, making patients 
choose treatments that may not be the best choice in each 
particular circumstance. I agree with the authors that the 
“serotonin” hypothesis does not fully explain the mechanism 
of the serotonin reuptake inhibitors (SSRIs) in the treatment 
of anxiety disorders and depression. 
In my clinical treatment of patients, consumer advertising 
is not only not helpful but often causes signiﬁ  cant 
management problems. In addition, consumer advertising 
only focuses on expensive, patented medications and not 
on equally good generic alternatives. A good example is the 
consumer advertising of “the purple pill,” Nexium, while 
generic Prilosec, equally effective in almost all patients, is not 
advertised.
Let’s prohibit all consumer advertising of patented 
medications. It will save physicians much headache, and 
patients or their insurers a great deal of money.  
Karl Rickels
University of Pennsylvania 
Philadelphia, Pennsylvania, United States of America
E-mail: krickels@mail.med.upenn.edu 
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Should Industry Speak the Loudest 
in Informing the Public on Medical 
Matters? 
Gordon McCarter
Lacasse and Leo make an important contribution in 
the debate over prescription drug advertising [1]. 
Their demonstration of the ubiquity of the scientiﬁ  cally 
unsupported claim that serotonin reuptake inhibitors (SSRIs) 
“correct a chemical imbalance” points out the need for better 
regulation of direct-to-consumer (DTC) advertising by the 
United States Food and Drug Administration (FDA). This 
question then leads to a larger issue: how does the public get 
unbiased information to rationally choose between different 
treatment options that may be available for particular 
diseases.
First, it should be emphasized that the “monoamine 
hypothesis” of depression has not been proven wrong; 
it is simply very incomplete. Inhibiting the serotonin 
and/or norepinephrine transporter(s) clearly relieves 
the symptoms of major depression for many patients, and 
the safety proﬁ  les of the current SSRIs and serotonin/
norepinephrine reuptake inhibitors (SNRIs) are quite 
favorable. Nevertheless, the exclusively pharmaceutical and 
commercial approach to the treatment of depression that 
the typical consumer is exposed to in the media does a grave 
disservice to those who might beneﬁ  t from the many other 
treatment options available.
The realization that depression is a true physical disease 
has allowed millions of sufferers to seek treatment, and 
has removed much of the guilt and shame (or proud 
forbearance) that sometimes resulted from a predominately 
psychodynamic conception of the causes of depression. 
Earlier, when very little else was known about the etiology of 
the disease, it might have been helpful to describe the action 
of the available drugs to patients as “correcting an imbalance” 
in brain neurotransmitters. Now, with so much more known 
or strongly suggested about the biology of depression, it 
is irresponsible for anyone in the medical community to 
describe it as simply a “chemical imbalance.” The implications 
of the heritability of a predisposition, the role of early life 
trauma, the involvement of stress hormones, the observations 
of neuronal atrophy, and the possible link to hippocampal 
neurogenesis all have implications for treatment that lead 
in many directions other than simply a pharmaceutical 
approach. These include nutrition, exercise, and certain 
forms of psychotherapy, especially cognitive-behavioral 
therapy.
But how would a depressed person know about all these 
treatment options? If lucky, the person might be induced, 
perhaps by DTC advertising, to visit a doctor, who would 
then describe current thinking about depression and try to 
determine the best treatment for the patient’s situation. But 
doctors are extremely overworked these days, and they, too, 
are targeted by the advertising of pharmaceutical companies. 
Indeed, “medical education” is a huge industry through 
which these ﬁ  rms, at one remove, attempt to inﬂ  uence 
medical practice by the sponsoring of meetings, symposia, 
and journal supplements and by the well-remunerated 
enlistment of academic “opinion leaders” to present and to be 
credited as authors for what are usually ghost-written pieces. 
The result is a knowledge environment that is overwhelmingly 
dominated by the perspective of commercial interests.
The solution to this problem, of course, is education, 
both of physicians and of patients. A nice way to achieve 
this, and to refrain from infringing on anyone’s free speech, 
would be to require that any expenditure on advertising by 
pharmaceutical or medical device manufacturers be matched 
by contributions to an unbiased education fund administered 
by the FDA, the National Institutes of Health (NIH), or 
both. This fund could be used to produce public service 
announcements of clear and balanced information regarding 
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the particular therapeutic area that the company’s product 
addresses. However it is funded, the federal government is 
the only entity with the resources and reach to be an effective 
counterweight to the commercial medical perspective. 
There are few roles that may be as important for a national 
government than the protection of its citizens’ health 
through effective regulation of the presentation of medical 
information.  
Gordon McCarter
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Vallejo, California, United States of America
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Authors’ Reply
We are pleased to see that our Essay [1] has sparked this 
discussion regarding consumer advertising of psychiatric 
medications.
There seems to be no disagreement with our main theses—
antidepressant advertisements do not accurately represent 
the evidence base from psychopharmacology, experimental 
psychiatry, and neuroscience; are not strictly based on 
the United States Food and Drug Administration (FDA)-
approved prescribing label; and may mislead consumers. 
We believe many have bought into the serotonergic 
hypothesis of depression/generalized anxiety/social anxiety/
obsessive-compulsive disorder/panic disorder/post-traumatic 
stress/bulimia/premenstrual dysphoric disorder largely 
because the serotonin reuptake inhibitor (SSRI) medications 
are licensed for these conditions. We reemphasize that 
pathophysiology cannot be established through clinical 
efﬁ  cacy [2], yet this critical point seems to have been largely 
overlooked, particularly by regulators.
At the date of this letter, the advertising we presented in 
our Essay is still widespread, and quite visible on consumer 
advertising Web sites of SSRI manufacturers.  
Jeffrey R. Lacasse (jeffreylacasse@comcast.net)
Florida State University
Tallahassee, Florida, United States of America
Jonathan Leo (jleo1@tampabay.rr.com)
Lake Erie College of Osteopathic Medicine
Bradenton, Florida, United States of America
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Other Studies Show Aspirin Use Is High 
Jonathan Brown
The importance of prophylactic aspirin use in both developed 
and developing countries can hardly be overemphasized. I 
am troubled, however, by Stafford and colleagues’ failure to 
cite and discuss United States studies that show much higher 
rates of antithrombotic use than they report [1]. Using a 
cross-sectional postal survey of 2,500 Kaiser Permanente 
members with atherosclerotic cardiovascular disease, Brown 
et al. [2] found that 84% were currently taking prophylactic 
aspirin (72%) or a prescription agent (12%, usually warfarin) 
in 1999. In an earlier study of another nonproﬁ  t-integrated 
US medical care system, HealthPartners, O’Connor et al. [3] 
similarly found that 71% of members with clinically diagnosed 
coronary heart disease were taking aspirin. These results are 
almost triple the approximately 25% that Stafford et al. now 
report for the 1999–2000 time period (the low point in their 
time series), and about double the 34% that Stafford [4] 
previously reported from the National Ambulatory Medical 
Care Study for patients with coronary heart disease.
Two factors probably account for these differences. First, 
Stafford et al.’s federal surveys of ambulatory care encounters 
miss a signiﬁ  cant proportion of aspirin use. Studies in a 
variety of populations that used direct patient surveys and 
other methods, some of which are cited in Brown et al. [1], 
have found higher rates of aspirin use in a variety of settings 
than Stafford et al. have reported over the years. Second, 
nonproﬁ  t-integrated medical care programs emphasize and 
promote aspirin aggressively and effectively. Their members 
probably have higher rates of aspirin use than individuals in 
other US care-delivery settings.
The experience of the nonproﬁ  t-integrated systems is 
also important because it calls into question Stafford et al.’s 
suggestion, emphasized in PLoS’s accompanying synopsis, 
that direct-to-consumer advertising of statins explains the 
1997–2000 dip in aspirin use in their data. Kaiser Permanente 
and HealthPartners members were equally exposed to direct 
advertising, but maintained high aspirin use during this 
period—despite probably also using statins (and angiotensin 
converting enzyme [ACE] inhibitors) at higher rates than 
individuals in other US care-delivery settings. 
The US nonproﬁ  t HMO experience nevertheless reinforces 
the authors’ main conclusion that “aggressive and targeted 
interventions are needed to enhance provider and patient 
adherence to consensus guidelines for CVD risk reduction” [1]. 
Aggressive and targeted interventions are exactly what these 
settings use. Major structural factors such as lack of universal 
health insurance, fee-for-service rather than population-based 
orientation, and failure to use comprehensive electronic 
medical record systems will continue to hamper the US, 
however. Direct-to-consumer advertising, although symptomatic, 
pales in importance against these other problems.  
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Authors’ Reply
Brown correctly points out that the rates of prophylactic 
aspirin use from our study [1] were much lower than 
the rates reported in some other United States studies, 
particularly those of Brown et al. [2] and O’Connor et al 
[3]. The latter studies represent practices in two large, 
integrated health maintenance organizations, which may 
represent special examples of best practices. Based on two 
nationally representative ambulatory-care surveys, our results 
are comparable to those from the Third National Health and 
Nutrition Examination Survey (NHANES III) [4]. As detailed 
in our discussion of data limitations, National Ambulatory 
Medical Care Survey and National Hospital Ambulatory 
Medical Care Survey data are reported by physicians on a 
per-patient visit basis, which may generate different ﬁ  ndings 
than a population-based survey. Complementing earlier 
studies, our ﬁ  ndings suggest that underutilization of aspirin 
as a cost-effective cardiovascular prevention strategy remains 
widespread in the US.
It is critical to discern factors associated with variation in 
aspirin use. This can lead to targeting some subpopulations 
for improvement or, alternatively, for attempts to 
promulgate features of best practice to other settings. For 
example, our analysis suggested that after adjusting for 
level of cardiovascular risk, women had signiﬁ  cantly lower 
use of aspirin than men. As Brown points out, nonproﬁ  t-
integrated medical care exempliﬁ  es one system in which 
prophylactic use of aspirin can be aggressively and effectively 
implemented. These settings have mechanisms in place that 
encourage sustained aspirin therapy, including guidelines, 
messages to clinicians, nursing-care management, alerts 
and routines embedded in electronic medical records, 
and direct mailings to patients [2]. Greater adoption of 
these mechanisms outside of integrated systems may have a 
favorable impact on national patterns of aspirin use. The issue 
of making our nation’s health-care system more responsive to 
available evidence is a complex undertaking. We agree with 
Brown that direct-to-consumer drug advertising is a secondary 
factor in current patterns of aspirin use. Nonetheless, among 
other factors, direct-to-consumer drug advertising should be 
included as a potential barrier that may interfere with the 
translation of clinical evidence into practice.  
Randall S. Stafford (rstafford@stanford.edu)
Veronica Monti
Jun Ma
Stanford University Medical School
Stanford, California, United States of America
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Does Genetic Testing Really Improve 
the Prediction of Future Type 2 
Diabetes?
A. Cecile J. W. Janssens, Marta Gwinn, Subramony 
Subramonia-Iyer, Muin J. Khoury 
From their study on the genetic prediction of future type 
2 diabetes (T2D), Lyssenko and colleagues conclude that 
“genetic testing might become a future approach to identify 
individuals at risk of developing T2D” [1]. One of their 
most striking ﬁ  ndings is an impressive 21.2-fold increased 
risk for T2D in obese carriers of the PPARG PP and CAPN10 
SNP43/44 GG/TT genotypes with elevated fasting plasma 
glucose (FPG).
A closer look at their results reveals that the hazard ratio 
of 21.2 was obtained by comparing the T2D risks of persons 
who have all three risk factors (“risk genotypes,” obesity, and 
elevated FPG) with those who have none of these factors. This 
hazard ratio, thus, measures the combined increase in risk 
due to PPARG PP and CAPN10 SNP43/44 GG/TT genotypes, 
obesity, elevated FPG, and their interactions. Among obese 
persons with elevated FPG, the incidence of T2D was 44.7% 
in carriers of risk genotypes and 10.7% in persons with 
other genotypes, yielding a risk ratio of 4.2 (95% conﬁ  dence 
interval [CI], 2.3–7.8; follow-up time, age, and sex were not 
taken into account)—a result that is statistically signiﬁ  cant 
but considerably smaller. Furthermore, genotyping did not 
signiﬁ  cantly alter the risk of T2D in any other subgroups 
deﬁ  ned by body mass index (BMI) or FPG. Apart from this, 
the case for predictive genetic testing depends not merely 
on the magnitude of the risk ratio, but rather on the extent 
to which the test results are useful for improving prediction 
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of disease [2]. In this study, does testing for PPARG PP 
and CAPN10 SNP43/44 genotypes improve the prediction 
of T2D based on BMI and FPG alone? The usefulness of 
genetic testing for predicting disease can be evaluated by 
comparing the discriminative accuracy of predictions based 
on models that do and do not include the genetic test results 
[3]. The discriminative accuracy of a test is indicated by its 
sensitivity and speciﬁ  city (dichotomous test results), or by 
the area under the receiver-operating characteristic (ROC) 
curve (variable test results) [4]. Sensitivity is the probability 
of a positive test result among persons who will develop the 
disease, and speciﬁ  city is the probability of a negative test 
result among persons who will not develop the disease. In a 
perfect test, both sensitivity and speciﬁ  city equal one. For tests 
with variable (not dichotomous) results, a cut-off probability 
must be chosen. Sensitivity and speciﬁ  city of the test will vary 
with the choice of cut-off probability. When sensitivity and 
speciﬁ  city are calculated for each possible cut-off value and 
plotted as an ROC curve, the area under the curve (AUC) 
measures the discriminative ability of the test. AUC can vary 
from 0.5 (no discrimination) to one (perfect discrimination) 
[4].
Using the data presented by Lyssenko et al. [1], we 
estimated the discriminative accuracy of predictions of 
T2D risks that did and did not take genotype into account. 
We used logistic regression to obtain the risks of T2D for 
all individuals in the study, considering three different 
prediction models. In the ﬁ  rst model, risk of T2D was 
predicted by BMI (BMI less than 30 kg/m2; BMI greater than 
or equal to 30 kg/m2) and FPG (FPG less than 5.6 mmol/l; 
FPG greater than or equal to 5.6 mmol/l). The second model 
included BMI, FPG, and carrier status of the combined 
PPARG PP and CAPN10 SNP43/44 GG/TT genotypes, and 
the third model also included all interaction effects among 
the three predictors. ROC curves and estimated values for 
the AUC were obtained using SPSS 11.0.1. For predictions 
of T2D risk based on BMI and FPG alone, the AUC was 0.68 
(95% CI, 0.63–.073), indicating a moderately discriminative 
accuracy. In comparison, AUCs of approximately 0.77 
have been estimated for both serum cholesterol testing for 
predicting coronary heart disease and neuropsychological 
testing for predicting Alzheimer disease in asymptomatic 
persons [5,6]. When genotype was added to the predictive 
model including BMI and FPG, AUC remained the same 
(0.68; 95% CI, 0.63–0.73, for main effect only), even when all 
interaction effects were considered (0.69; 95% CI, 0.64–0.74). 
The AUCs of the three prediction models are presented in 
Figure 1. Thus, the data of Lyssenko et al. suggest that genetic 
testing for PPARG PP and CAPN10 SNP43/44 genotypes 
will not improve the prediction of T2D in the presence of 
information on the nongenetic factors, BMI and FPG. The 
differences in our conclusions are explained by the fact that 
Lyssenko et al. focused on the highest-risk category rather 
than on differences in risk among all participants. Individuals 
who had 21.2- fold increased risk were already in the highest-
risk category based on BMI and FPG alone. Genotyping only 
further subdivided each risk category, without substantially 
altering the ranking of the categories. And ﬁ  nally, the 21.2-
fold risk applied to the second-smallest subgroup, which 
included only 38 of the 2,243 participants. Testing for PPARG 
PP and CAPN10 SNP43/44 genotypes did not change the 
T2D risk for the vast majority of the population.  
A. Cecile J. W. Janssens (a.janssens@erasmusmc.nl)
Erasmus University Medical Center Rotterdam
Rotterdam, Netherlands 
Marta Gwinn
Muin J. Khoury 
Centers for Disease Control and Prevention
Atlanta, Georgia, United States of America
Subramony Subramonia-Iyer
Cambridge Genetics Knowledge Park 
Cambridge, United Kingdom
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Authors’ Reply
In their correspondence to our paper, “Genetic Prediction of 
Type 2 Diabetes” [1], Janssens et al. question whether genetic 
testing really will improve prediction of future type 2 diabetes 
(T2D) [2].
Their criticism is well taken and important for the 
discussion on the causes of T2D. It is assumed, although not 
yet proven, that T2D results from the complex interaction 
between multiple genetic variants and environmental risk 
factors. In an earlier paper [3], we listed three of those risk 
factors: family history of T2D, body mass index (BMI) greater 
than or equal to 30 kg/m2, and non-normal fasting plasma 
glucose (FPG) greater than 5.5 mmol/l. Two of these risk 
factors (BMI and FPG) were replicated in a study of Israeli 
military men [4]. If we assume that T2D results from the 
interaction between these risk factors and genetic variants, 
it is not unreasonable to test whether genetic risk factors 
improve the predictive value of the environmental risk 
factors.
Therefore, the main objective of our analysis was to ﬁ  nd 
a joint genetic and environmental model that accurately 
describes the effects on the time distribution of the age at 
onset, and to use that model to quantify the genetic and 
environmental effects. For that purpose, we have performed 
forward stepwise multivariate Cox regression analysis, adding 
one covariate at a time. The resulting multivariate model has 
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then been tested against a “null” model with a likelihood-
ratio test to assess the overall ﬁ  t of the model. To address 
the question asked in the introduction, we choose to study 
the effects of having all the signiﬁ  cant risk factors elevated 
against the effects of having none by using the estimates in 
the resulting model. This approach is open for discussion; 
one alternative approach would be the approach presented 
by Janssens et al.
They make a group division and use logistic regression to 
assess genetic effects on the development of T2D. There are 
two drawbacks with this approach. The ﬁ  rst is that by dividing 
the population into subgroups one lowers the power to ﬁ  nd 
signiﬁ  cant effects and also obtains large variances in the 
estimated effects, thus getting a large degree of uncertainty in 
both signiﬁ  cance and size of the estimated effects. Secondly, 
logistic regression disregards the fact that individuals 
have been followed prospectively. In contrast, we perform 
calculations of estimated effects in the obtained multivariate 
model, thereby using all the available data in the variance 
calculations. This allows us to assess the size of an increment 
of a risk factor for prediction of the disease, e.g., the 
estimated hazard ratio (HR) for a continuous covariate is the 
ratio of the hazards for an increase of one in the covariate. 
Using our multivariate model, the genetic factors confer a 
T2D risk of the same magnitude (HR, 3.69) as, e.g., FPG (HR, 
3.25) and BMI (HR, 1.77). 
Janssens et al. claim that a receiver-operating characteristic 
(ROC) analysis on our data does not support the claim that 
there is signiﬁ  cant gene effect for discriminative purposes. 
However, Janssens et al. perform an ROC and an area under 
the curve (AUC) analysis based on a logistic regression, thus 
treating each individual as affected versus nonaffected and 
not taking into consideration age effects, the drawbacks of 
which are discussed above. 
An ROC analysis may not be the best way to describe 
modest effects of genetic variants contributing to risk of a 
polygenic disorder such as T2D. This is further hampered 
by the use of longitudinal data with several time points. 
Although the ROC analysis recently [5] has been applied to 
survival analysis data, the complexity of the situation in T2D 
limits its value. Using this approach, we obtain an AUC of 
0.76 for the full model and an AUC of 0.75 for the model 
excluding genetic effects. 
However, an ROC analysis could work for genetic 
prediction of a monogenic disorder such as maturity-onset 
diabetes of the young (MODY). MODY 3 is a dominant form 
of early-onset diabetes with strong penetrance, and is caused 
by mutations in the hepatocyte nuclear factor 1, HNF-1α gene 
[6]. In an analysis of 33 carriers of MODY mutations followed 
for a mean of 4.7 years, the AUC for diagnosis of MODY was 
0.86.
We should keep in mind that we have only tested a few 
potential common genetic variants contributing to T2D. 
It was recently suggested that only approximately 20 genes 
may be needed to explain 50% of the disease burden in the 
population [7]. However, for individual genetic prediction, 
we need to establish how much of the relative risk (λs) is 
accounted for by genetic variants. For this purpose, we 
need to know all variants which contribute to risk of T2D. 
Hopefully, genome-wide single nucleotide polymorphism 
(SNP) scans in the future can provide us with that 
information.  
Valeriya Lyssenko (valeri.lyssenko@med.lu.se)
Dragi Anevski
Peter Almgren 
Leif Groop
Lund University
Malmö, Sweden
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Community-Based Learning in a Time 
of Conﬂ  ict 
Bishnu Giri, P. Ravi Shankar
We read with interest the Editorial “Improving Health by 
Investing in Medical Education” [1]. The emphasis on 
problem-based, community-oriented, integrated teaching 
was of special interest. In Nepal, though community-based 
learning (CBL) has been carried out for many years, the 
majority of teaching still occurs in acute hospital settings. The 
ongoing conﬂ  ict in Nepal has had an impact on all sectors, 
including medical education. CBL has been quite severely 
affected. 
The Institute of Medicine (IOM), Kathmandu, the ﬁ  rst 
medical college in Nepal, organizes community diagnosis 
programs (comprehensive assessments of the health status of 
a community in relation to its social, physical, and biological 
environment) [2]. 
The Manipal College of Medical Sciences (MCOMS), 
Pokhara, Nepal, admits mainly students from Nepal, India, 
and Sri Lanka for the undergraduate medical (MBBS) 
course. The revised curriculum of Kathmandu University 
[3], to which the college is afﬁ  liated, emphasises CBL. 
Community diagnosis, school health studies, family studies, 
participation in rural health camps, and health education 
are the various activities carried out. The Department of 
Pharmacology conducts exercises to acquaint students with 
the processes of the Community Drug Program (a system of 
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community ﬁ  nancing of drugs) and with the investigation 
of medicine use in peripheral health centres using drug-use 
indicators. 
Around six years ago, when the insurgency was just 
taking root, students used to visit remote areas in Kaski 
(the district which includes the city of Pokhara) and 
neighbouring districts as a part of their community 
diagnosis studies. They stayed there for a few days, 
interacting closely with local communities. Community 
ﬁ  eld trips were, however, gradually curtailed with the rise 
of the insurgency, and were ﬁ  nally limited to the Pokhara 
Valley. The college authorities were apprehensive about 
the possible harm to students and faculty members. Other 
colleges have also curtailed their CBL because of the spread 
of the insurgency. A friend from IOM wrote recently saying, 
“The prevailing situation is affecting the site selection for 
community studies. The studies used to be conducted at 
sites outside the Kathmandu Valley, but these days the sites 
are preferentially chosen inside the valley” (S. Gurung, 
personal communication).
In private medical colleges, students mainly come from 
economically well-off families and have little idea of poverty 
and deprivation. Some of my friends were surprised to see 
a family living in a small hut on a hillside in a village just 
outside Pokhara. Young women often give birth without 
trained medical assistance in rural areas. Women carry 
heavy loads of ﬁ  rewood and fodder for their cattle along 
steep mountain trails well into late pregnancy. Empathy and 
sympathy for the less fortunate may be qualities lacking in 
doctors who are not exposed to rural life. Their impression 
of the community’s health status may be lopsided. In their 
future practice, students may not consider the patient’s 
economic status while prescribing treatment. 
The deleterious effects of conﬂ  ict on health status of a 
community are an established fact. Urban students having 
little experience in rural Nepal may ﬁ  nd it difﬁ  cult to adjust if 
posted to a rural health centre after graduation. The present 
curtailment of CBL in rural areas may lead to production 
of less competent manpower and ineffective policymaking 
in the not too distant future. We sincerely hope that, with 
the hope of peace being reestablished, CBL in Nepal will be 
strengthened and expanded.  
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